TCI Express Ltd Investor Presentation for FY&Q March 2024 results
Max Financial Services Ltd Investor Presentation for FY&Q March 2024 Results
Novartis CEO: Here's why we boosted our full-year guidance
Novartis Contract Manufacturing
COMMENTS
Investors
Learn how Novartis uses science-based innovation to create value over the longer term for our company, our shareholders, and society. ... Novartis ASCO Investor Event June 02, 2024 | Chicago, USA . ... Investors event calendar View recent presentations and learn more about upcoming events. July 18, 2024 Second quarter 2024 results Basel ...
2022 Q4 and Full Year Results Presentation & Transcript
Novartis assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates. Print. View the 2022 Q4 and Full Year results presentation and read the transcript slide by slide.
PDF Q1 2024 Results
Investor presentation April 23, 2024 Investor presentation April 23, 2024 Q1 2024 Results. Nov 1 23 2024 2 Content Company overview Financial review ... in subsequent reports filed with, or furnished to, the US Securities and Exchange Commission. Novartis is providing the information in this presentation as of this date and does not undertake ...
2023 Q4 and Full Year Results Presentation & Transcript
Novartis assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates. Print. View the 2023 Q4 and Full Year results presentation and read the transcript slide by slide.
2021 Q4 and Full Year Results Presentation & Transcript
Novartis assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates. Print. View the 2021 Q4 and Full Year results presentation and read the transcript slide by slide.
PDF Novartis announces intention to separate Sandoz business to create a
7 AUGUST 25, 2022 | NOVARTIS INVESTOR PRESENTATION Free Cash Flow % of sales 2021 2027 Return on Invested Capital 2021 2027 Core Operating Income Margin 2021 2027+ Sales % cc, CAGR +4% 2021 2027 New-Novartis expectations (illustrative only) Incremental benefit from spin-off Benefits to New-Novartis
PDF prod1.financial.novartis.com
Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be id
PDF Q4 2022 Results
Company overview Financial review 2023 priorities Appendix 2 Investor Relations │ Q4 2022 Results Disclaimer 2 NOVARTIS Q4 RESULTS | FEBRUARY 1, 2023 | NOVARTIS INVESTOR PRESENTATION This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Refo rm Act of 1995, that can generally be identified by
2023 Q4 and Full Year Results Presentation & Transcript
View the 2023 Q4 and Full Year results presentation and read the transcript slide by slide Slide 1 - Samir Shah, Global Head Investor Relations Thank you very much, and good morning and good afternoon, everybody. Thank you again for listening to our ... Slide 3 - Vasant Narasimhan - CEO of Novartis Thank you, Samir, and thanks, everyone ...
PDF Novartis Q2 2020 Results
5 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Continuing operations1, % cc vs. PY Strong operational performance Delivering on innovation Strong H1 performance despite the impact of COVID-19 H1 results more representative of performance as Q1 forward purchasing largely reversed in Q2-1% 6% 19% 6% Q2 2020 H1 2020 Net ...
Novartis (NVS) Investor Presentation
Novartis (NVS) Investor Presentation - Slideshow. Apr. 13, 2022 2:09 PM ET Novartis AG (NVS) Stock, NVSEF Stock. SA Transcripts. 147.16K Followers. Follow.
Novartis : Q3 2020 Results Investor presentation
8 Novartis Q3 Results | October 27, 2020 | Novartis Investor Presentation. In-market growth drivers, major launches and a rich pipeline expected to sustain our long-term growth. 15 ongoing / upcoming expected major launches. 80+ submissions planned to 2022 1. 50+ late stage programs 2.
PDF Q1 2021 Results
President, Novartis Pharmaceuticals Susanne Schaffert President, Novartis Oncology John Tsai Head of Global Drug Development and CMO Richard Saynor CEO, Sandoz Tom Kendris Chief Legal Officer Ad Interim Samir Shah Global Head Investor Relations 3 Novartis Q1 Results | April 27, 2021 | Novartis Investor Presentation
2022 Q3 Results Presentation & Transcript
Novartis assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates. View the 2022 Q3 results presentation and read the transcript slide by slide.
Novartis (NVS) Investor Presentation
Novartis (NVS) Investor Presentation - Slideshow. Oct. 01, 2021 2:44 PM ET Novartis AG (NVS) Stock, NVSEF Stock. 1 Like. SA Transcripts. 147.24K Follower s. The following slide deck was published ...
PDF Q1 2022 Results
6 NOVARTIS Q1 RESULTS | APRIL 26, 2022 | NOVARTIS INVESTOR PRESENTATION Constant currencies (cc) is a non-IFRS measure; explanation of non-IFRS measures can be found on page 35 of Condensed Interim Financial Report. Unless otherwise noted, all growth rates refer to same period in PY nm -not meaningful 1. Innovative Medicines division 1 GROWTH
Novartis : investors presentation
13 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation. Operational excellence. Zolgensma ® strong launch (June) with FY 2019 sales of USD 361m. Broad access, strong patient demand. Q3 end (~) YE (~) Patients treated commercially.
PDF Q4 2021 Results
9 NOVARTIS Q4 RESULTS | FEBRUARY 2, 2022 | NOVARTIS INVESTOR PRESENTATION IM -Innovative Medicines division HS -Hidradenitis suppurativa DLBCL -Diffuse large B cell lymphoma MM -Multiplemyeloma 1. Q4 sales growth for Group, IM and Sandoz includes +1% point impact from a reclassification of contract manufacturing from other revenue to ...
PDF Investor Presentation
Investor Presentation NASDAQ: PNT ... looking statement contained in this presentation, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements generally relate to future events or the Company's ...
PDF Q3 2020 Results
Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be id
PDF Q3 2021 Results
5 Novartis Q3 Results | October 26, 2021 | Novartis Investor Presentation Consistent strong performance since 2018. Confident in our sales growth outlook ~ CAGR 4% to 2025 9M 2018 32.4 9M 2019 9M 2020 37.1 9M 2021 34.3 36.3 Core OpInc USD bn, % CAGR cc Sales USD bn, % CAGR cc +220bps +90bps Innovative Medicines Core margin (%), growth bps cc
Jun 24, 2024 Press Release for Alnylam
Investor Webcast Information. ... which is being developed and commercialized by Alnylam's partner, Novartis. Alnylam has a deep pipeline of investigational medicines, ... the expected timing of the presentation of full data from the HELIOS-B clinical trial and the filing of a U.S. Supplemental New Drug Application for vutrisiran; ...
Company overview
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.
Investor Relations Analyst
Your responsibilities include, but are not limited to:Collaborate with stakeholders across the company to gather information related to quarterly financial performance and ensure the accuracy of data and alignment of external messagingSupport development of earnings and investor communications materials including presentations, press releases and financial reportsMonitor sell-side coverage and ...
IMAGES
VIDEO
COMMENTS
Learn how Novartis uses science-based innovation to create value over the longer term for our company, our shareholders, and society. ... Novartis ASCO Investor Event June 02, 2024 | Chicago, USA . ... Investors event calendar View recent presentations and learn more about upcoming events. July 18, 2024 Second quarter 2024 results Basel ...
Novartis assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates. Print. View the 2022 Q4 and Full Year results presentation and read the transcript slide by slide.
Investor presentation April 23, 2024 Investor presentation April 23, 2024 Q1 2024 Results. Nov 1 23 2024 2 Content Company overview Financial review ... in subsequent reports filed with, or furnished to, the US Securities and Exchange Commission. Novartis is providing the information in this presentation as of this date and does not undertake ...
Novartis assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates. Print. View the 2023 Q4 and Full Year results presentation and read the transcript slide by slide.
Novartis assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates. Print. View the 2021 Q4 and Full Year results presentation and read the transcript slide by slide.
7 AUGUST 25, 2022 | NOVARTIS INVESTOR PRESENTATION Free Cash Flow % of sales 2021 2027 Return on Invested Capital 2021 2027 Core Operating Income Margin 2021 2027+ Sales % cc, CAGR +4% 2021 2027 New-Novartis expectations (illustrative only) Incremental benefit from spin-off Benefits to New-Novartis
Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be id
Company overview Financial review 2023 priorities Appendix 2 Investor Relations │ Q4 2022 Results Disclaimer 2 NOVARTIS Q4 RESULTS | FEBRUARY 1, 2023 | NOVARTIS INVESTOR PRESENTATION This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Refo rm Act of 1995, that can generally be identified by
View the 2023 Q4 and Full Year results presentation and read the transcript slide by slide Slide 1 - Samir Shah, Global Head Investor Relations Thank you very much, and good morning and good afternoon, everybody. Thank you again for listening to our ... Slide 3 - Vasant Narasimhan - CEO of Novartis Thank you, Samir, and thanks, everyone ...
5 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Continuing operations1, % cc vs. PY Strong operational performance Delivering on innovation Strong H1 performance despite the impact of COVID-19 H1 results more representative of performance as Q1 forward purchasing largely reversed in Q2-1% 6% 19% 6% Q2 2020 H1 2020 Net ...
Novartis (NVS) Investor Presentation - Slideshow. Apr. 13, 2022 2:09 PM ET Novartis AG (NVS) Stock, NVSEF Stock. SA Transcripts. 147.16K Followers. Follow.
8 Novartis Q3 Results | October 27, 2020 | Novartis Investor Presentation. In-market growth drivers, major launches and a rich pipeline expected to sustain our long-term growth. 15 ongoing / upcoming expected major launches. 80+ submissions planned to 2022 1. 50+ late stage programs 2.
President, Novartis Pharmaceuticals Susanne Schaffert President, Novartis Oncology John Tsai Head of Global Drug Development and CMO Richard Saynor CEO, Sandoz Tom Kendris Chief Legal Officer Ad Interim Samir Shah Global Head Investor Relations 3 Novartis Q1 Results | April 27, 2021 | Novartis Investor Presentation
Novartis assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates. View the 2022 Q3 results presentation and read the transcript slide by slide.
Novartis (NVS) Investor Presentation - Slideshow. Oct. 01, 2021 2:44 PM ET Novartis AG (NVS) Stock, NVSEF Stock. 1 Like. SA Transcripts. 147.24K Follower s. The following slide deck was published ...
6 NOVARTIS Q1 RESULTS | APRIL 26, 2022 | NOVARTIS INVESTOR PRESENTATION Constant currencies (cc) is a non-IFRS measure; explanation of non-IFRS measures can be found on page 35 of Condensed Interim Financial Report. Unless otherwise noted, all growth rates refer to same period in PY nm -not meaningful 1. Innovative Medicines division 1 GROWTH
13 Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation. Operational excellence. Zolgensma ® strong launch (June) with FY 2019 sales of USD 361m. Broad access, strong patient demand. Q3 end (~) YE (~) Patients treated commercially.
9 NOVARTIS Q4 RESULTS | FEBRUARY 2, 2022 | NOVARTIS INVESTOR PRESENTATION IM -Innovative Medicines division HS -Hidradenitis suppurativa DLBCL -Diffuse large B cell lymphoma MM -Multiplemyeloma 1. Q4 sales growth for Group, IM and Sandoz includes +1% point impact from a reclassification of contract manufacturing from other revenue to ...
Investor Presentation NASDAQ: PNT ... looking statement contained in this presentation, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements generally relate to future events or the Company's ...
Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be id
5 Novartis Q3 Results | October 26, 2021 | Novartis Investor Presentation Consistent strong performance since 2018. Confident in our sales growth outlook ~ CAGR 4% to 2025 9M 2018 32.4 9M 2019 9M 2020 37.1 9M 2021 34.3 36.3 Core OpInc USD bn, % CAGR cc Sales USD bn, % CAGR cc +220bps +90bps Innovative Medicines Core margin (%), growth bps cc
Investor Webcast Information. ... which is being developed and commercialized by Alnylam's partner, Novartis. Alnylam has a deep pipeline of investigational medicines, ... the expected timing of the presentation of full data from the HELIOS-B clinical trial and the filing of a U.S. Supplemental New Drug Application for vutrisiran; ...
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.
Your responsibilities include, but are not limited to:Collaborate with stakeholders across the company to gather information related to quarterly financial performance and ensure the accuracy of data and alignment of external messagingSupport development of earnings and investor communications materials including presentations, press releases and financial reportsMonitor sell-side coverage and ...